User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells

Primary tabs

Valenzuela Valderrama, Manuel Alejandro [UCL] Glorieux, Christophe [UCL] Stockis, Julie [UCL] Sid, Brice [UCL] Sandoval Calquin, Juan Marcelo [UCL] Felipe, Karina B. [UCL] Kviecinski, Maicon R. [UCL] Verrax, Julien [UCL] Buc Calderon, Pedro [UCL]

Background: Standard therapy for acute promyelocytic leukaemia (APL) includes retinoic acid (all-trans retinoic acid (ATRA)), which promotes differentiation of promyelocytic blasts. Although co-administration of arsenic trioxide (ATO) with ATRA has emerged as an effective option to treat APL, the molecular basis of this effect remains unclear. Methods: Four leukaemia cancer human models (HL60, THP-1, NBR4 and NBR4-R2 cells) were treated either with ATO alone or ATO plus ATRA. Cancer cell survival was monitored by trypan blue exclusion and DEVDase activity assays. Gene and protein expression changes were assessed by RT-PCR and western blot. Results: ATO induced an antioxidant response characterised by Nrf2 nuclear translocation and enhanced transcription of downstream target genes (that is, HO-1, NQO1, GCLM, ferritin). In cells exposed to ATO plus ATRA, the Nrf2 nuclear translocation was prevented and cytotoxicity was enhanced. HO-1 overexpression reversed partially the cytotoxicity by ATRA-ATO in HL60 cells. The inhibitory effects of ATRA on ATO-mediated responses were not observed in either the ATRA-resistant NB4-R2 cells or in NB4 cells pre-incubated with the RARα antagonist Ro-41-52-53. Conclusions: The augmented cytotoxicity observed in leukaemia cells following combined ATO-ATRA treatment is likely due to inhibition of Nrf2 activity, thus explaining the efficacy of combined ATO-ATRA treatment in the APL therapy. © 2014 Cancer Research UK.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2014
Language Anglais
Journal information "The British journal of cancer" - Vol. 111, no. 5, p. 874-882 (2014)
Peer reviewed yes
Publisher Nature Publishing Group on behalf of Cancer Research ((United Kingdom) London)
issn 0007-0920
e-issn 1532-1827
Publication status Publié
Affiliations UCL - SSS/LDRI - Louvain Drug Research Institute
UCL - SSS/DDUV - Institut de Duve
Links
  1. Ablain Julien, Leiva Magdalena, Peres Laurent, Fonsart Julien, Anthony Elodie, de Thé Hugues, Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies, 10.1084/jem.20122337
  2. Alarifi S, Onco Targets Ther, 6, 75 (2013)
  3. Apfel C., Bauer F., Crettaz M., Forni L., Kamber M., Kaufmann F., LeMotte P., Pirson W., Klaus M., A retinoic acid receptor alpha antagonist selectively counteracts retinoic acid effects., 10.1073/pnas.89.15.7129
  4. Chendamarai E., Balasubramanian P., George B., Viswabandya A., Abraham A., Ahmed R., Alex A. A., Ganesan S., Lakshmi K. M., Sitaram U., Nair S. C., Chandy M., Janet N. B., Srivastava V. M., Srivastava A., Mathews V., Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy, 10.1182/blood-2011-11-393264
  5. Chou W.-C., Jie C., Kenedy A. A., Jones R. J., Trush M. A., Dang C. V., Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells, 10.1073/pnas.0306687101
  6. Davison K, Côté S, Mader S, Miller W H, Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines, 10.1038/sj.leu.2402876
  7. Duprez E, Benoit G, Flexor M, Lillehaug J R, Lanotte M, A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities, 10.1038/sj.leu.2401683
  8. Goto E., Tomita A., Hayakawa F., Atsumi A., Kiyoi H., Naoe T., Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment, 10.1182/blood-2011-01-329433
  9. Gozzelino Raffaella, Jeney Viktoria, Soares Miguel P., Mechanisms of Cell Protection by Heme Oxygenase-1, 10.1146/annurev.pharmtox.010909.105600
  10. Gupta Kalpana, Chakrabarti Amitabha, Rana Sonia, Ramdeo Ritu, Roth Bryan L., Agarwal Munna L., Tse William, Agarwal Mukesh K., Wald David N., Securinine, a Myeloid Differentiation Agent with Therapeutic Potential for AML, 10.1371/journal.pone.0021203
  11. Heasman Sally-Anne, Zaitseva Lyubov, Bowles Kristian M., Rushworth Stuart A., MacEwan David J., Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1, 10.18632/oncotarget.321
  12. Huang ME, Blood, 72, 567 (1998)
  13. Iland H. J., Bradstock K., Supple S. G., Catalano A., Collins M., Hertzberg M., Browett P., Grigg A., Firkin F., Hugman A., Reynolds J., Di Iulio J., Tiley C., Taylor K., Filshie R., Seldon M., Taper J., Szer J., Moore J., Bashford J., Seymour J. F., , All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4), 10.1182/blood-2012-02-410746
  14. Isbister Geoffrey K, Dawson Andrew H, Whyte Ian M, Arsenic trioxide poisoning: a description of two acute overdoses, 10.1191/0960327104ht459cr
  15. Kamimura Tomohiko, Miyamoto Toshihiro, Harada Mine, Akashi Koichi, Advances in therapies for acute promyelocytic leukemia, 10.1111/j.1349-7006.2011.02045.x
  16. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri E S, Baehrecke E H, Blagosklonny M V, El-Deiry W S, Golstein P, Green D R, Hengartner M, Knight R A, Kumar S, Lipton S A, Malorni W, Nuñez G, Peter M E, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G, Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009, 10.1038/cdd.2008.150
  17. Lang E., Grudic A., Pankiv S., Bruserud O., Simonsen A., Bjerkvig R., Bjoras M., Boe S. O., The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling, 10.1182/blood-2011-10-388496
  18. Lau A., Zheng Y., Tao S., Wang H., Whitman S. A., White E., Zhang D. D., Arsenic Inhibits Autophagic Flux, Activating the Nrf2-Keap1 Pathway in a p62-Dependent Manner, 10.1128/mcb.01748-12
  19. Ma Qiang, Role of Nrf2 in Oxidative Stress and Toxicity, 10.1146/annurev-pharmtox-011112-140320
  20. Marasca R, Haematologica, 84, 963 (1999)
  21. Miller WH, Cancer Res, 62, 3893 (2002)
  22. Morales Alejo A., Gutman Delia, Cejas Pedro J., Lee Kelvin P., Boise Lawrence H., Reactive Oxygen Species Are Not Required for an Arsenic Trioxide-induced Antioxidant Response or Apoptosis, 10.1074/jbc.m806546200
  23. Nakamura Shunsuke, Nagano Satoshi, Nagao Hiroko, Ishidou Yasuhiro, Yokouchi Masahiro, Abematsu Masahiko, Yamamoto Takuya, Komiya Setsuro, Setoguchi Takao, Arsenic Trioxide Prevents Osteosarcoma Growth by Inhibition of GLI Transcription via DNA Damage Accumulation, 10.1371/journal.pone.0069466
  24. Nicholson Donald W., Ali Ambereen, Thornberry Nancy A., Vaillancourt John P., Ding Connie K., Gallant Michel, Gareau Yves, Griffin Patrick R., Labelle Marc, Lazebnik Yuri A., Munday Neil A., Raju Sayyaparaju M., Smulson Mark E., Yamin Ting-Ting, Yu Violeta L., Miller Douglas K., Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis, 10.1038/376037a0
  25. Park J. H., ATRA plus arsenic gets another "A" in APL, 10.1182/blood-2012-07-439547
  26. Patatanian E., Thompson D. F., Retinoic acid syndrome: a review, 10.1111/j.1365-2710.2008.00935.x
  27. Rahman Irfan, Kode Aruna, Biswas Saibal K, Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method, 10.1038/nprot.2006.378
  28. Rushworth Stuart A., MacEwan David J., The Role of Nrf2 and Cytoprotection in Regulating Chemotherapy Resistance of Human Leukemia Cells, 10.3390/cancers3021605
  29. Rushworth Stuart A., Zaitseva Lyubov, Langa Susana, Bowles Kristian M., MacEwan David J., FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism, 10.18632/oncotarget.168
  30. Saeed S, Logie C, Stunnenberg H G, Martens J H A, Genome-wide functions of PML–RARα in acute promyelocytic leukaemia, 10.1038/sj.bjc.6606095
  31. Sekeres Mikkael A., Maciejewski Jaroslaw P., Erba Harry P., Afable Manuel, Englehaupt Ricki, Sobecks Ronald, Advani Anjali, Seel Sherry, Chan Josephine, Kalaycio Matt E., A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia, 10.1002/cncr.25686
  32. Sharma Manish, Khan Hassan, Thall Peter F., Orlowski Robert Z., Bassett Roland L., Shah Nina, Bashir Qaiser, Parmar Simrit, Wang Michael, Shah Jatin J., Hosing Chitra M., Popat Uday R., Giralt Sergio A., Champlin Richard E., Qazilbash Muzaffar H., A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid : Bortezomib, ATO, AA, & Melphalan for MM, 10.1002/cncr.26517
  33. Shen ZX, Blood, 89, 3354 (1997)
  34. Tallman M. S., Altman J. K., How I treat acute promyelocytic leukemia, 10.1182/blood-2009-07-216457
  35. Valenzuela Manuel, Pérez‐Pérez Guillermo, Corvalán Alejandro H., Carrasco Gonzalo, Urra Hery, Bravo Denisse, Toledo Héctor, Quest Andrew F. G., Helicobacter pylori–Induced Loss of the Inhibitor‐of‐Apoptosis Protein Survivin Is Linked to Gastritis and Death of Human Gastric Cells, 10.1086/656143
  36. Vardiman J. W., Thiele J., Arber D. A., Brunning R. D., Borowitz M. J., Porwit A., Harris N. L., Le Beau M. M., Hellstrom-Lindberg E., Tefferi A., Bloomfield C. D., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, 10.1182/blood-2009-03-209262
  37. Wang H., Liu K., Geng M., Gao P., Wu X., Hai Y., Li Y., Li Y., Luo L., Hayes J. D., Wang X. J., Tang X., RXR  Inhibits the NRF2-ARE Signaling Pathway through a Direct Interaction with the Neh7 Domain of NRF2, 10.1158/0008-5472.can-12-3386
  38. Wang Lisu, Weng Ching-Yi, Wang Ying-Jan, Wu Ming-Jiuan, Lipoic acid ameliorates arsenic trioxide-induced HO-1 expression and oxidative stress in THP-1 monocytes and macrophages, 10.1016/j.cbi.2011.02.001
  39. Wang X. J., Hayes J. D., Henderson C. J., Wolf C. R., Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha, 10.1073/pnas.0709483104
  40. Wetzler Meir, Andrews Chris, Ford Laurie A., Tighe Sheila, Barcos Maurice, Sait Sheila N. J., Block AnneMarie W., Nowak Norma J., Baer Maria R., Wang Eunice S., Baumann Heinz, Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia : Phase 1 ATO/Hidac/Ida in AML <60 Years, 10.1002/cncr.26097
  41. Zhang X. W., Yan X. J., Zhou Z. R., Yang F. F., Wu Z. Y., Sun H. B., Liang W. X., Song A. X., Lallemand-Breitenbach V., Jeanne M., Zhang Q. Y., Yang H. Y., Huang Q. H., Zhou G. B., Tong J. H., Zhang Y., Wu J. H., Hu H. Y., de The H., Chen S. J., Chen Z., Arsenic Trioxide Controls the Fate of the PML-RAR  Oncoprotein by Directly Binding PML, 10.1126/science.1183424
  42. Zhou D.-C., Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo, 10.1182/blood.v99.4.1356
Bibliographic reference Valenzuela Valderrama, Manuel Alejandro ; Glorieux, Christophe ; Stockis, Julie ; Sid, Brice ; Sandoval Calquin, Juan Marcelo ; et. al. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. In: The British journal of cancer, Vol. 111, no. 5, p. 874-882 (2014)
Permanent URL http://hdl.handle.net/2078.1/159795